Flomax Risk Found for BPH Patients Facing Cataract Surgery
According to a 2009 article in Journal of the
American Medical Association (JAMA), use of the medication tamsulosin
(Flomax, Flomaxtra and Urimax, depending upon which nation it is sold
in) to treat male urination difficulties (enlarged prostate, benign
prostate hyperplasia, BPH) within two weeks of cataract surgery is
associated with an increased risk of serious
postoperative ophthalmic adverse events such as retinal detachment or
Benign prostatic hyperplasia (BPH; enlarged prostate) affects nearly 3
of 4 men by the age of 70 years, with symptoms of BPH including
urination difficulties. Flomax (tamsulosin) is commonly prescribed for
BPH, and it had sales of more than $1 billion in 2007. Some research
has suggested that this drug may increase the risk of complications,
such as intraoperative floppy iris syndrome (IFIS) during cataract
surgery, a procedure that approximately 5 percent of elderly U.S.
residents undergo every year.
In the analysis of adverse events following cataract surgery, patients
who received tamsulosin in the 14 days before surgery had a 2.3 times
higher risk of a serious adverse event (7.5 percent vs. 2.7 percent of
Flomax copyright is owned by its owner. This website is not
associated with the manufacturer or vendor of Flomax or any other
The opinions expressed on this website are not to be considered as medical
information or advice. Every person and every situation is different.
For any serious condition, you should consult qualified medical
personnel. All copyrights are owned by their owners. This website is not affiliated with the manufacturer or vendor of any medical product, equipment or service.